What lab tests are used to diagnose polycythemia vera?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Testing for Polycythemia Vera

The essential lab tests for diagnosing polycythemia vera are: (1) complete blood count with differential to confirm elevated hemoglobin/hematocrit, (2) JAK2 mutation testing (both V617F and exon 12), and (3) serum erythropoietin level to distinguish primary from secondary causes. 1, 2

Initial Laboratory Panel

Order these tests immediately when PV is suspected:

  • Complete blood count (CBC) with red cell indices and manual differential to document elevated hemoglobin (>18.5 g/dL in men, >16.5 g/dL in women) or hematocrit (>55% in men, >49.5% in women), and assess for accompanying thrombocytosis or leukocytosis 1, 2

  • Reticulocyte count to evaluate bone marrow response 1

  • Serum ferritin and transferrin saturation to identify coexisting iron deficiency, which commonly masks the full extent of erythrocytosis in PV 1, 2

  • Peripheral blood smear review by a qualified hematologist to identify abnormal morphology and assess for left shift 2

Diagnostic Molecular and Biochemical Testing

JAK2 mutation testing is the cornerstone diagnostic test:

  • JAK2 V617F mutation (exon 14) is present in up to 97% of PV cases and should be ordered as the first-line molecular test 3, 1, 2, 4

  • JAK2 exon 12 mutations should be tested if JAK2 V617F is negative, as these account for most remaining PV cases 1

  • Serum erythropoietin (EPO) level is critical for distinguishing PV from secondary polycythemia: low or inappropriately normal EPO (below reference range) is highly specific (>90%) for PV, though sensitivity is only 64-70% 3, 5

WHO Diagnostic Criteria Application

The World Health Organization criteria require either:

  1. Both major criteria PLUS one minor criterion, OR
  2. First major criterion PLUS two minor criteria 3, 1, 2

Major criteria:

  • Elevated hemoglobin (>16.5 g/dL women, >18.5 g/dL men) OR hematocrit (>49% women, >52% men) OR documented sustained increase >2 g/dL from baseline 3, 1
  • Presence of JAK2 mutation (V617F or exon 12) 3, 1

Minor criteria:

  • Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis with prominent erythroid and megakaryocytic proliferation) 3, 2
  • Subnormal serum erythropoietin level 3, 2
  • Endogenous erythroid colony formation in vitro 3, 2

Bone Marrow Examination

Bone marrow biopsy is required if JAK2 mutation is positive to confirm PV diagnosis and assess for trilineage myeloproliferation, and is essential for establishing baseline histomorphology 2, 6

Bone marrow biopsy should also be performed if diagnosis remains unclear after initial workup to exclude other myeloid neoplasms 2

Additional Laboratory Tests to Exclude Secondary Causes

When EPO is elevated or normal, systematically evaluate for secondary polycythemia:

  • Arterial blood gas or pulse oximetry to assess for hypoxemia from chronic lung disease, right-to-left shunts, or sleep apnea 5

  • Carboxyhemoglobin level if smoking history is present, as smoker's polycythemia from chronic carbon monoxide exposure is the most common secondary cause 5, 2

  • Renal function tests (creatinine, BUN) to screen for kidney disease causing inappropriate EPO production 5

  • Liver function tests (AST, ALT, bilirubin) to screen for hepatocellular carcinoma 5

  • Abdominal imaging (ultrasound or CT) to screen for EPO-producing tumors: renal cell carcinoma, hepatocellular carcinoma, uterine leiomyomas, pheochromocytoma 5, 2

Critical Diagnostic Pitfalls to Avoid

Do not assume normal EPO excludes PV – EPO sensitivity for PV is only 64-70%; normal EPO with elevated hemoglobin still requires JAK2 testing 5

Do not overlook iron deficiency coexisting with erythrocytosis – iron-deficient red blood cells have reduced oxygen-carrying capacity and deformability, and high RDW with normal or low MCV suggests this combination 1, 2

Do not miss masked PV – a subset of patients have normal hemoglobin/hematocrit due to blood dilution or coincidental blood loss but still have underlying PV with JAK2 mutations; these patients often present with thrombosis as their first manifestation 7

Do not rely on a single measurement – repeat hemoglobin and hematocrit measurements to confirm persistent elevation, as single measurements are unreliable 1, 2

When to Refer to Hematology

Immediate hematology referral is indicated for:

  • Positive JAK2 mutation 2
  • Hemoglobin >20 g/dL with symptoms of hyperviscosity (headache, visual disturbances, dizziness) 2
  • Unexplained splenomegaly with elevated blood counts 2
  • Unusual site thrombosis (portal vein, hepatic vein, mesenteric vein) even with normal blood counts 7

References

Guideline

Assessment Protocol for Incidental Erythrocytosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Polycythemia Vera and Secondary Erythrocytosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Polycythaemia vera.

Nature reviews. Disease primers, 2025

Guideline

Secondary Polycythemia Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.